

# SARC Biannual Meeting Agenda

May 29<sup>th</sup>, 2009

The Rosen Plaza Hotel, Orlando, FL

8:00 am - 12:45 pm

<b>8:00-8:15</b>	<b>Welcome/SARC Update</b> <ul style="list-style-type: none"><li>• Career development Award Presentation</li></ul>	L. Baker
<b>8:15 -9:30</b>	<b>Review of Trials</b> <ul style="list-style-type: none"><li>• SARC 012 Phase 2 Src kinase Inhibitor Recurrent Osteosarcoma Localized to Lung</li><li>• SARC 009 Phase 2 Dasatinib in metastatic sarcoma</li><li>• SARC 006 Phase 2 MPNST: Sporadic versus NF1 associated/ SARC 016 Phase 2 RAD001 with and without Bevacizumab in NF1 and sporadic MPSNT</li><li>• SARC 005 Phase 2 Adjuvant Therapy High Risk Uterine Leiomyosarcoma</li></ul>	R. Chugh L. Helman S. Schuetze, J. Trent, K. Wathen B. Widemann M. Hensley
<b>9:30-9:45</b>	<b>Break</b>	
<b>9:45-9:50</b>	<b>SARC Unified Database Project</b>	R. Benjamin
<b>9:50-10:35</b>	<b>Continue Review of Trials</b> <ul style="list-style-type: none"><li>• SARC 004 Phase 2 Neoadjuvant Imatinib in DFSP</li><li>• SARC 003 Phase 2 Gemcitabine/Docetaxel in Bone Sarcoma</li></ul> <b>Review of Pending Trials</b> <ul style="list-style-type: none"><li>• SARC 013 Phase 3 IGF-1R/Ewing's sarcoma</li><li>• SARC 015 Phase 2 IGF-1R in WT GIST</li><li>• Imatinib PK Study</li></ul>	S. Schuetze E. Fox  P. Meyers M. von Mehren S. George J. Trent
<b>10:35- 10:45</b>	<b>Participation Committee Updates</b>	S. George
<b>10:45- 11:15</b>	<b>Chawla/Rosenfeld Developmental Therapeutics Symposium</b> <ul style="list-style-type: none"><li>• Immunotherapeutic options for management of metastatic sarcoma</li></ul>	S. Rosenberg
<b>11:15- 12:45</b>	<b>Closed Session: SARC Investigators Only</b>	D. Reinke